Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HPV-16/18 AS04-adjuvanted vaccine in women aged 26 years and older
NL-OMON38271Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection and Cervical Cancer (CC) (2 arms), sponsored by GSK. Primary endpoints: Combined endpoint using lesional component PCR and Combined endpoint using HPV TAA. Started Mar 2006; status: active, not recruiting.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON38271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38271.